KD014

KD014 (DX-2400) is a human monoclonal antibody (mAb) targeting MMP14 (Ki: 0.9 nM) . KD014 inhibits TGFβ and SMAD2/3 activity, increases macrophage numbers and iNOS expression, and shifts macrophage phenotype toward anti-tumor M1-like. KD014 has anti-tumor activity in three different tumor models (MDA-MB-231, MDA-MB-435, and PC3) . KD014 can be used in breast cancer research[1][2].

Product Specifications

Product Name Alternative

DX-2400; DX-2410

UNSPSC

12352203

Target

MMP; NO Synthase; TGF-beta/Smad; TGF-β Receptor

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

96.98

Molecular Weight

(144.01 kDa)

References & Citations

[1]Ager EI, et al. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. J Natl Cancer Inst. 2015 Feb 20;107 (4) :djv017.|[2]Devy L, et al. Antitumor efficacy of DX-2400, a potent and selective human antibody MMP-14 inhibitor discovered using phage display technology[J]. Cancer Research, 2007, 67 (9_Supplement) : 5618-5618.